چکیده (انگلیسی):

Prevalence of dengue transmission has been alarmed by an estimate of 390 million infections
per annum. Urban encroachment, ecological disruption and poor sanitation are all
contributory factors of increased epidemiology. Complication however arises from the
fact that dengue virus inherently exists as four different serotypes. Secondary infection is
often manifested in the more severe form, such that antibody-dependent enhancement
(ADE) could aggravate ailment by allowing pre-existing antibodies to form complexes
with infecting viruses as means of intrusion. Consequently, increased viraemic titter and
suppression of antiviral response are observed. Deep concerns are thus expressed in
regards to escalating trend of hospitalisation and mortality rates. In Malaysia, situation is
exacerbated by improper clinical management and pending vector control operations. As
a preparedness strategy against the potential deadly dengue pandemic, the call for
development of a durable and cost-effective dengue vaccine against all infecting serotypes
is intensified. Even though several vaccine candidates are currently being evaluated
in clinical trials, uncertainties in regards to serotypes interference, incomplete protection
and dose adequacy have been raised. Instead of sole reliance on outsourcing, production
of local vaccine should be considered in coherent to government's efforts to combat
against dengue.